Literature DB >> 10862520

Molecular analysis of the N-acetyltransferase 1 gene (NAT1*) using polymerase chain reaction-restriction fragment-single strand conformation polymorphism assay.

J M Lo-Guidice1, D Allorge, D Chevalier, H Debuysère, F Fazio, L J Lafitte, F Broly.   

Abstract

One major interest to analyse the extent of N-acetyltransferase 1 (NAT1*) allelic variation in the human population stems to a great extent from the possible association of interindividual differences in the metabolism of aromatic amines with certain chemically induced diseases, including cancer. Considering the increasing number of mutations in the NAT1 gene that are detected, NAT1* genotyping using conventional polymerase chain reaction (PCR) restriction fragment length polymorphism (RFLP) or allele-specific amplification assays has become complicated. We developed a rapid and powerful strategy allowing the full characterization of NAT1* alleles. This method, based on single-strand conformation polymorphism analysis of a unique PCR product encompassing the entire intronless NAT1*-coding region along with additional flanking segments in the 5' and 3' untranslated regions, was then applied to DNA samples from 270 individuals. Nine NAT1* allelic variants, including two novel (NAT1*28 and NAT1*29), and 15 different genotypes were identified. This approach could be advantageously used in epidemiological studies to provide more definite data on suspected associations between NAT1* genotype and certain pathological processes.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10862520     DOI: 10.1097/00008571-200006000-00003

Source DB:  PubMed          Journal:  Pharmacogenetics        ISSN: 0960-314X


  5 in total

Review 1.  A meta-analysis of the NAT1 and NAT2 polymorphisms and prostate cancer: a huge review.

Authors:  Chunming Gong; Xueying Hu; Yong Gao; Yunfei Cao; Feng Gao; Zengnan Mo
Journal:  Med Oncol       Date:  2010-01-23       Impact factor: 3.064

2.  Functional properties of an alternative, tissue-specific promoter for human arylamine N-acetyltransferase 1.

Authors:  David F Barker; Anwar Husain; Jason R Neale; Benjamin D Martini; Xiaoyan Zhang; Mark A Doll; J Christopher States; David W Hein
Journal:  Pharmacogenet Genomics       Date:  2006-07       Impact factor: 2.089

3.  Polymorphisms of cytochrome P4501A2 and N-acetyltransferase genes, smoking, and risk of pancreatic cancer.

Authors:  Donghui Li; Li Jiao; Yanan Li; Mark A Doll; David W Hein; Melissa L Bondy; Douglas B Evans; Robert A Wolff; Renato Lenzi; Peter W Pisters; James L Abbruzzese; Manal M Hassan
Journal:  Carcinogenesis       Date:  2005-06-29       Impact factor: 4.944

4.  Polymorphism of N-acetyltransferase 1 and correlation between genotype and phenotype in a Thai population.

Authors:  Veerapol Kukongviriyapan; Auemduan Prawan; Benjamart Warasiha; Wichittra Tassaneyakul; Jareerat Aiemsa-ard
Journal:  Eur J Clin Pharmacol       Date:  2003-07-19       Impact factor: 2.953

5.  Functional analysis of arylamine N-acetyltransferase 1 (NAT1) NAT1*10 haplotypes in a complete NATb mRNA construct.

Authors:  Lori M Millner; Mark A Doll; Marcus W Stepp; J Christopher States; David W Hein
Journal:  Carcinogenesis       Date:  2011-11-22       Impact factor: 4.944

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.